Fig. 2.

Protection of mice from acute lethal GVHD with bortezomib administration. (A) Bortezomib administration delays GVHD mortality in an aggressive model of acute lethal GVHD. B6 (H-2^b) recipients of 15 million BALB/c (H-2^d) bone marrow and 40 million spleen cells were treated with 10 μg per dose of bortezomib or vehicle control (PBS) daily from day 0 through day +3 post-BMT. Significant increases in survival were observed in bortezomib-treated animals (▾) compared with PBS-treated mice (▪)(P < 0.0001). (B) Bortezomib administration protects mice from GVHD mortality in a moderately aggressive model of acute lethal GVHD. B6 (H-2^b) recipients of 15 million BALB/c (H-2^d) bone marrow and 25 million spleen cells were treated with 10 μg per dose of bortezomib or vehicle control (PBS) daily from day 0 through +2 post-BMT. Significant increases in survival were observed in bortezomib-treated animals (▾) compared with PBS-treated mice (▾) (P < 0.0001). Results from one of three independent experiments are presented for A and B. Each experiment consists of 8–10 mice per treatment group in GVHD induction arms and 3–4 mice in BMT control arms.